Faculty Information   
   日本語 >>
  1. TOP page
    2. >
  2. Clinical Medicine Seminars

Journal
Presentation
    （Last updated : 2023-09-29 17:45:20）
  Hashimoto Teppei
   Department   Specialty Division  , Clinical Medicine Seminars
   Position  
■ Journal
1. Original article　 Expressions of circadian clock genes represent disease activities of RA patients treated with biological DMARDs. 2020/03
2. Case report　 Acquired marked hypertriglyceridemia with anti-GPIHBP1 antibodies. 2020/05
3. Introduction　 Cell-Free DNA in rheumatoid arthritis. 2021/08
4. Original article　 Increased Circulating Cell-Free DNA in Eosinophilic Granulomatosis With Polyangiitis: Implications for Eosinophil Extracellular Traps and Immunothrombosis. 2022/01
5. Original article　 Serum B cell activating factor(BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis. 2022/12
6. Original article　 Tocilizumab suppresses NF-kappa B activation via toll-like receptor 9 signaling by reducing cell-free DNA in rheumatoid arthritis. 2023/07
Display 5 items
Display all(6)
■ Presentation
1. Systemic Immune-inflammation index in rheumatoid arthritis patients:relation to disease activity. （Poster presentation，General Lecture） 2019/06/13
2. Circulating cell free DNA released from eosinophils is a practical biomarker in patients with eosinophilic granulomatosis with polyangiitis. （Poster presentation，General Lecture） 2019/11/11
3. Relationship between YKL-40, VEGF, and IL-5 in borderline mPAP and pulmonary hypertension in systemic sclerosis. （Poster presentation，General Lecture） 2019/11/11
4. The baseline soluble GP130 is associated with the response of rheumatoid arthritis patients to sarilmab. （Poster presentation，General Lecture） 2020/07/03
5. Circulating cell free DNA as a biomarker in Eosinophilic granulomatosis with polyangiitis. （Web announcement，Symposium/Workshop/Panel Discussion） 2020/09/17
6. Increased levels of serum wisteria floribunda agglutininpositive Mac-2 binding protein in rheumatic diseases including SLE. （Newspaper announcement） 2021/06/02
7. Successful treatment of checkpoint inhibitor-induced arthritis with the IL-6 receptor inhibitor Sarilumab. （Poster presentation，General Lecture） 2021/08/28
8. Plasma cell-free DNA is a useful biomarker for tocilizumab therapy in rheumatoid arthritis. （Poster presentation，General Lecture） 2021/11/08
9. Neutrophil count reduction 1month after initiating sarilumab and baseline serum soluble gp130 levels can independently predict clinical remission within 3 month in rheumatoid arthritis patients. （Newspaper announcement） 2022/06/01
10. The baseline serum soluble TNF receptor level are associated with the response of rheumatoid arthritis
patients to JAKinibs. （Newspaper announcement） 2022/06/01
11. YKL-40-mediated Inflammatory pathogenesis common to polymyositis/dermatomyositis. （Poster presentation，General Lecture） 2022/10/14
12. Predictive factors for the flare of patients with rheumatoid arthritis (RA) in ultrasound remission(US-R). （Poster presentation，General Lecture） 2023/06/01
Display 5 items
Display all(12)
mail